



## Clinical trial results: Aprepitant – effect and safety in treatment of atopic dermatitis Summary

EudraCT number	2013-002029-40
Trial protocol	SE
Global end of trial date	31 March 2015

### Results information

Result version number	v1 (current)
This version publication date	10 April 2021
First version publication date	10 April 2021

### Trial information

#### Trial identification

Sponsor protocol code	1001
-----------------------	------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Karolinska Institutet
Sponsor organisation address	17177, Stockholm, Sweden,
Public contact	Dep of dermatology, Karolinska Univ, Karolinska institutet, klas.nordlind@karolinska.se
Scientific contact	Dep of dermatology, Karolinska Univ, Karolinska institutet, klas.nordlind@karolinska.se

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	31 March 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 March 2015
Global end of trial reached?	Yes
Global end of trial date	31 March 2015
Was the trial ended prematurely?	No

Notes:

---

---

**General information about the trial**

---

Main objective of the trial:

To investigate the effect of Aprepitant (Emend) on atopic dermatitis and pruritus.

---

Protection of trial subjects:

The protocol was approved by the local ethics committee and by the Medical Products Agency. Safety was assessed by recording adverse events at the second visit. The patients could also contact the clinic at any time during the treatment period if they observed any suspected side-effects.

---

Background therapy: -

---

Evidence for comparator: -

---

Actual start date of recruitment	01 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

---

**Population of trial subjects**

---

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Sweden: 39
Worldwide total number of subjects	39
EEA total number of subjects	39

Notes:

---

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	39
From 65 to 84 years	0
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

The patients were recruited from dermatology clinics in the Stockholm area and examined at the Department of Dermatology, Karolinska University Hospital, Solna, Stockholm, Sweden, between October 2013 to March 2015.

### Pre-assignment

Screening details:

Patients had a moderate-severe (SCORAD > 20) AD and diagnosis was determined according to the Williams criteria. Exclusion criteria: other concomitant diseases or medications (except for contraceptives), skin type 5-6 according to Fitzpatrick, skin infections, pregnancy, breast-feeding. The washout period for prior systemic treatment was 2 months.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment group

Arm description:

The patients received 80 mg/day of aprepitant orally for 7 days in addition to standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer.

21 participants were enrolled, but 2 of those patients interrupted study treatment due to adverse events, specifically experienced transient side-effects, such as dizziness, impotence, headache (1 case) and lack of reactivity, dyspnoea and palpitations (the second case). Those 2 patients are not included in the baseline characteristics or analysis that is presented here.

Arm type	Experimental
Investigational medicinal product name	Aprepitant
Investigational medicinal product code	SUB20017
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

80 mg/day of aprepitant orally for 7 days.

Investigational medicinal product name	Hydrocortisone butyrate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden).

<b>Arm title</b>	Control group
------------------	---------------

Arm description:

Standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer.

Arm type	Standard topical treatment
----------	----------------------------

Investigational medicinal product name	Hydrocortisone butyrate
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden).

<b>Number of subjects in period 1</b>	Treatment group	Control group
Started	19	20
Completed	19	20

## Baseline characteristics

### Reporting groups

Reporting group title	Treatment group
Reporting group description:	
The patients received 80 mg/day of aprepitant orally for 7 days in addition to standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer.	
21 participants were enrolled, but 2 of those patients interrupted study treatment due to adverse events, specifically experienced transient side-effects, such as dizziness, impotence, headache (1 case) and lack of reactivity, dyspnoea and palpitations (the second case). Those 2 patients are not included in the baseline characteristics or analysis that is presented here.	
Reporting group title	Control group
Reporting group description:	
Standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer.	

Reporting group values	Treatment group	Control group	Total
Number of subjects	19	20	39
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	19	20	39
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	30.8	29.3	
standard deviation	± 8.4	± 9.2	-
Gender categorical			
Units: Subjects			
Female	7	16	23
Male	12	4	16
OSCORAD			
OSCORAD = objective SCORing of Atopic Dermatitis			
Units: Score			
arithmetic mean	40.5	37.0	
standard deviation	± 12.0	± 11.3	-
Visual analogue scale			
Units: Score			
arithmetic mean	5.5	6.7	
standard deviation	± 2.1	± 2.2	-
IgE levels			
Units: kU/l			

arithmetic mean standard deviation	903.7 ± 1.391	876.5 ± 1.934	-
Scratching movements Units: Registered number daily arithmetic mean standard deviation	77.3 ± 97.9	65.0 ± 100.9	-
Montgomery Åsberg Depression Rating Scale Units: Score arithmetic mean standard deviation	5.6 ± 4.9	9.3 ± 8.9	-
Hospital Anxiety and Depressive scale Units: Score arithmetic mean standard deviation	3.4 ± 4.1	6.6 ± 4.8	-
Substance P Units: pmol/g arithmetic mean standard deviation	98.7 ± 54.4	105.6 ± 46.5	-

## End points

### End points reporting groups

Reporting group title	Treatment group
Reporting group description: The patients received 80 mg/day of aprepitant orally for 7 days in addition to standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer. 21 participants were enrolled, but 2 of those patients interrupted study treatment due to adverse events, specifically experienced transient side-effects, such as dizziness, impotence, headache (1 case) and lack of reactivity, dyspnoea and palpitations (the second case). Those 2 patients are not included in the baseline characteristics or analysis that is presented here.	
Reporting group title	Control group
Reporting group description: Standard topical treatment with a moderately strong steroid cream (hydrocortisone butyrate; Locoid®, LEO Pharma AB, Malmö, Sweden) and a moisturizer.	

### Primary: OSCORAD Post-treatment

End point title	OSCORAD Post-treatment
End point description: Objective SCORing of Atopic Dermatitis, arbitrary units (range 0–83)	
End point type	Primary
End point timeframe: Day 7 of treatment.	

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: Score				
arithmetic mean (standard deviation)	32.0 (± 11.2)	26.7 (± 14.7)		

### Statistical analyses

Statistical analysis title	Difference OSCORAD post-treatment
Statistical analysis description: Difference in OSCORAD between treatment and control after 7 days of treatment.	
Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

---

**Secondary: Visual analogue scale Post-treatment**

---

End point title	Visual analogue scale Post-treatment
-----------------	--------------------------------------

End point description:

Visual analogue scale, arbitrary units (range 0–10).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 7 of treatment.

---

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: Score				
arithmetic mean (standard deviation)	3.8 ( $\pm$ 2.2)	4.1 ( $\pm$ 3.0)		

---

**Statistical analyses**

---

Statistical analysis title	Difference VAS post-treatment
----------------------------	-------------------------------

Statistical analysis description:

Difference in Visual Analogue Scale between treatment and control after 7 days of treatment.

Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

---

**Secondary: IgE levels Post-treatment**

---

End point title	IgE levels Post-treatment
-----------------	---------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Day 7 of treatment.

---



End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: kE/l				
arithmetic mean (standard deviation)	937.9 ( $\pm$ 1.403)	821.1 ( $\pm$ 1.754)		

## Statistical analyses

Statistical analysis title	Difference IgE levels post treatment
Statistical analysis description: Difference in IgE levels between treatment and control after 7 days of treatment.	
Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	Wilcoxon (Mann-Whitney)

## Secondary: Scratching movements Post-treatment

End point title	Scratching movements Post-treatment
End point description:	
End point type	Secondary
End point timeframe: Day 7 of treatment.	

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: Registered number daily				
arithmetic mean (standard deviation)	48.3 ( $\pm$ 62.6)	34.7 ( $\pm$ 45.0)		

## Statistical analyses

Statistical analysis title	Difference Scratching movements post-treatment
Statistical analysis description: Difference in Scratching movements between treatment and control after 7 days of treatment.	
Comparison groups	Treatment group v Control group

Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

### Secondary: Montgomery Åsberg Depression Rating Scale Post-treatment

End point title	Montgomery Åsberg Depression Rating Scale Post-treatment
End point description:	Montgomery Åsberg Depression Rating Scale, arbitrary units (range 0–54).
End point type	Secondary
End point timeframe:	Day 7 of treatment.

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: Score				
arithmetic mean (standard deviation)	4.0 (± 5.3)	6.5 (± 5.9)		

### Statistical analyses

Statistical analysis title	Difference Depression scale post-treatment
Statistical analysis description:	Difference in Montgomery Åsberg Depression Rating Scale between treatment and control after 7 days of treatment.
Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

### Secondary: HAD Post-treatment

End point title	HAD Post-treatment
End point description:	Hospital Anxiety and Depressive scale, arbitrary units (range 0–21).
End point type	Secondary
End point timeframe:	Day 7 of treatment.

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: Score				
arithmetic mean (standard deviation)	3.5 ( $\pm$ 3.2)	4.8 ( $\pm$ 3.7)		

## Statistical analyses

Statistical analysis title	Difference HAD post-treatment
Statistical analysis description: Difference in HAD between treatment and control after 7 days of treatment.	
Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

## Secondary: Substance P Post-treatment

End point title	Substance P Post-treatment
End point description:	
End point type	Secondary
End point timeframe: Day 7 of treatment.	

End point values	Treatment group	Control group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	19	20		
Units: pmol/g				
arithmetic mean (standard deviation)	97.6 ( $\pm$ 50.3)	91.0 ( $\pm$ 32.7)		

## Statistical analyses

Statistical analysis title	Difference Substance P post-treatment
----------------------------	---------------------------------------

---

Statistical analysis description:

Difference in Substance P between treatment and control after 7 days of treatment.

Comparison groups	Treatment group v Control group
Number of subjects included in analysis	39
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	t-test, 2-sided

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Study start to day 7 of treatment.

Adverse event reporting additional description:

Recording of adverse events was done at the second visit (day 7 of treatment). The patients could also contact the clinic at any time during the treatment period if they observed any suspected side-effects. No frequency threshold was used, as all adverse events that arise were reported.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	ICD
-----------------	-----

Dictionary version	10-SE
--------------------	-------

### Reporting groups

Reporting group title	Treatment group
-----------------------	-----------------

Reporting group description: -

Reporting group title	Control group
-----------------------	---------------

Reporting group description: -

Serious adverse events	Treatment group	Control group	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 21 (0.00%)	0 / 20 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Treatment group	Control group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 21 (61.90%)	0 / 20 (0.00%)	
Product issues			
Headache, fatigue, dizziness, elevated liver enzymes, palpitations, dyspnoea...	Additional description: 13/21 participants in treatment reported transient AE: headache, fatigue, dizziness, elevated liver enzymes, palpitations, dyspnoea, altered ability to react, obstipation, stomach-ache, periocular dermatitis, erectile dysfunction, lack of reactivity.		
subjects affected / exposed	13 / 21 (61.90%)	0 / 20 (0.00%)	
occurrences (all)	13	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Patients in this study generally did not have worse than moderate pruritus, which may have had an impact on the results. There were different sex distributions in the 2 groups, thus it cannot be excluded that aprepitant exerts sex-specific effects.
--

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/29182791>